146 related articles for article (PubMed ID: 34485166)
1. Corrigendum: Combinatorial Strategies to Target Molecularand Signaling Pathways to Disarm Cancer Stem Cells.
Catara G; Colanzi A; Spano D
Front Oncol; 2021; 11():749040. PubMed ID: 34485166
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial Strategies to Target Molecular and Signaling Pathways to Disarm Cancer Stem Cells.
Catara G; Colanzi A; Spano D
Front Oncol; 2021; 11():689131. PubMed ID: 34381714
[TBL] [Abstract][Full Text] [Related]
3. Corrigendum: EXOSC5 as a Novel Prognostic Marker Promotes Proliferation of Colorectal Cancer via Activating the ERK and AKT Pathways.
Pan H; Pan J; Song S; Ji L; Lv H; Yang Z
Front Oncol; 2021; 11():670041. PubMed ID: 33898326
[TBL] [Abstract][Full Text] [Related]
4. Corrigendum: Targeting thymidylate synthase enhances the chemosensitivity of triple-negative breast cancer towards 5-FU-based combinatorial therapy.
Haritha NH; Nawab A; Vijayakurup V; Anto NP; Liju VB; Alex VV; Amrutha AN; Aiswarya SU; Swetha M; Vinod BS; Sundaram S; Guijarro MV; Herlevich T; Krishna A; Nestory NK; Bava SV; Sadasivan C; Zajac-Kaye M; Anto RJ
Front Oncol; 2023; 13():1302413. PubMed ID: 38162481
[TBL] [Abstract][Full Text] [Related]
5. Corrigendum: A Novel Invadopodia-Specific Marker for Invasive and Pro-Metastatic Cancer Stem Cells.
Huang SS; Liao WY; Hsu CC; Chan TS; Liao TY; Yang PM; Chen LT; Sung SY; Tsai KK
Front Oncol; 2021; 11():718849. PubMed ID: 34239806
[TBL] [Abstract][Full Text] [Related]
6. Corrigendum: Chemoresistance and Metastasis in Breast Cancer Molecular Mechanisms and Novel Clinical Strategies.
Cao J; Zhang M; Wang B; Zhang L; Zhou F; Fang M
Front Oncol; 2021; 11():745052. PubMed ID: 34485165
[TBL] [Abstract][Full Text] [Related]
7. Corrigendum: CDX2/mir-145-5p/SENP1 Pathways Affect LNCaP Cells Invasion and Migration.
He JH; Han ZP; Zou MX; He ML; Li YG; Zheng L
Front Oncol; 2021; 11():685219. PubMed ID: 34084751
[TBL] [Abstract][Full Text] [Related]
8. Corrigendum: LncRNA NBR2 Inhibits the Malignancy of Thyroid Cancer, Associated With Enhancing the AMPK Signaling.
Yang W; Zheng Z; Yi P; Wang S; Zhang N; Ming J; Tan J; Guo H
Front Oncol; 2021; 11():759471. PubMed ID: 34513720
[TBL] [Abstract][Full Text] [Related]
9. Corrigendum: Melanoma of Unknown Primary: Evaluation of the Characteristics, Treatment Strategies, Prognostic Factors in a Monocentric Retrospective Study.
Del Fiore P; Rastrelli M; Dall'Olmo L; Cavallin F; Cappellesso R; Vecchiato A; Buja A; Spina R; Parisi A; Mazzarotto R; Ferrazzi B; Grego A; Rotondi A; Benna C; Tropea S; Russano F; Filoni A; Bassetto F; Dei Tos AP; Alaibac M; Rossi CR; Pigozzo J; Chiarion Sileni V; Mocellin S
Front Oncol; 2021; 11():686051. PubMed ID: 33937089
[TBL] [Abstract][Full Text] [Related]
10. Corrigendum: The research progress on radiation resistance of cervical cancer.
Liang M; Sheng L; Ke Y; Wu Z
Front Oncol; 2024; 14():1430862. PubMed ID: 38826781
[TBL] [Abstract][Full Text] [Related]
11. Corrigendum: CLEC12A sensitizes differentially responsive breast cancer cells to the anti-cancer effects of artemisinin by repressing autophagy and inflammation.
Chatterjee R; Shukla A; Chakrabarti K; Chatterji U
Front Oncol; 2024; 14():1393626. PubMed ID: 38549942
[TBL] [Abstract][Full Text] [Related]
12. Corrigendum: Long Non-Coding RNA MIR570MG Causes Regorafenib Resistance in Colon Cancer by Repressing miR-145/SMAD3 Signaling.
Wei F; Wang M; Li Z; Wang Y; Zhou Y
Front Oncol; 2021; 11():818876. PubMed ID: 35071021
[TBL] [Abstract][Full Text] [Related]
13. Corrigendum: GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells
Booth L; West C; Von Hoff D; Dent P
Front Oncol; 2021; 11():677725. PubMed ID: 33937087
[TBL] [Abstract][Full Text] [Related]
14. Corrigendum: Proteome Analysis of USP7 Substrates Revealed Its Role in Melanoma Through PI3K/Akt/FOXO and AMPK Pathways.
Gao L; Zhu D; Wang Q; Bao Z; Yin S; Qiang H; Wieland H; Zhang J; Teichmann A; Jia J
Front Oncol; 2021; 11():736438. PubMed ID: 34368006
[TBL] [Abstract][Full Text] [Related]
15. Corrigendum: Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway.
Jain AS; Prasad A; Pradeep S; Dharmashekar C; Achar RR; Silina E; Stupin V; Amachawadi RG; Prasad SK; Pruthvish R; Syed A; Shivamallu C; Kollur SP
Front Oncol; 2021; 11():822865. PubMed ID: 34988031
[TBL] [Abstract][Full Text] [Related]
16. Corrigendum: PHF20 promotes glioblastoma cell malignancies through a
Ma Q; Long W; Xing C; Jiang C; Su J; Wang HY; Liu Q; Wang R
Front Oncol; 2023; 13():1157694. PubMed ID: 37035210
[TBL] [Abstract][Full Text] [Related]
17. Corrigendum: Pyruvate kinase M2 promotes prostate cancer metastasis through regulating ERK1/2-COX-2 signaling.
Guo W; Zhang Z; Li G; Lai X; Gu R; Xu W; Chen H; Xing Z; Chen L; Qian J; Xu S; Zeng F; Deng F
Front Oncol; 2024; 14():1323020. PubMed ID: 38410110
[TBL] [Abstract][Full Text] [Related]
18. Corrigendum: An Overview of Managements in Meningiomas.
Zhao L; Zhao W; Hou Y; Wen C; Wang J; Wu P; Guo Z
Front Oncol; 2020; 10():599431. PubMed ID: 33072614
[TBL] [Abstract][Full Text] [Related]
19. Corrigendum: Metabolic Dependencies in Pancreatic Cancer.
Vaziri-Gohar A; Zarei M; Brody JR; Winter JM
Front Oncol; 2018; 8():672. PubMed ID: 30805300
[TBL] [Abstract][Full Text] [Related]
20. Corrigendum: Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway.
Cao H; Li W; Zhou Y; Tan R; Yang Y; Zhou Y; Guo Q; Zhao L
Front Oncol; 2019; 9():990. PubMed ID: 31608242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
